NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 110 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $57,442,000 | -13.9% | 3,766,666 | 0.0% | 39.74% | -8.2% |
| Q4 2021 | $66,708,000 | -15.7% | 3,766,666 | 0.0% | 43.30% | -1.9% |
| Q3 2021 | $79,175,000 | +6.6% | 3,766,666 | 0.0% | 44.14% | +549.2% |
| Q2 2021 | $74,279,000 | -32.2% | 3,766,666 | 0.0% | 6.80% | -35.4% |
| Q1 2021 | $109,497,000 | -4.0% | 3,766,666 | 0.0% | 10.53% | -82.5% |
| Q4 2020 | $114,111,000 | +90.4% | 3,766,666 | 0.0% | 60.06% | +20.4% |
| Q3 2020 | $59,928,000 | -19.4% | 3,766,666 | 0.0% | 49.90% | +3.6% |
| Q2 2020 | $74,354,000 | +60.1% | 3,766,666 | 0.0% | 48.16% | +2.9% |
| Q1 2020 | $46,443,000 | -33.3% | 3,766,666 | 0.0% | 46.79% | -11.6% |
| Q4 2019 | $69,646,000 | +33.5% | 3,766,666 | -0.0% | 52.94% | +21.2% |
| Q3 2019 | $52,168,000 | -5.4% | 3,766,667 | 0.0% | 43.68% | +14.2% |
| Q2 2019 | $55,144,000 | – | 3,766,667 | – | 38.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $19,406,306 | 12.88% |
| StepStone Group LP | 1,573,357 | $1,683,492 | 0.38% |
| EcoR1 Capital, LLC | 6,435,518 | $6,886,004 | 0.23% |
| Euclidean Capital LLC | 1,984,336 | $2,123,240 | 0.23% |
| Boxer Capital, LLC | 500,000 | $535,000 | 0.03% |
| GSA CAPITAL PARTNERS LLP | 213,676 | $229 | 0.02% |
| Jasper Ridge Partners, L.P. | 303,492 | $324,736 | 0.02% |
| Carson Advisory Inc. | 15,850 | $16,960 | 0.02% |
| CORNERCAP INVESTMENT COUNSEL INC | 51,176 | $54,758 | 0.01% |
| Parkwood LLC | 68,314 | $73 | 0.01% |